MQI conducts and facilitates the development and commercialization of ethical pharmaceutical products (including generics) and medical devices, and provides manufacturing outsourcing and active pharmaceutical ingredients (APIs) outsourcing purchasing in China and Asia for companies in the United States.
MQI has a wide network and diverse connections with U.S. pharmaceutical manufacturers (including generics). As a result, we are able to identify and couple manufacturers with potential customers, both domestic and overseas, generating contracts for API inquiries. MQI is also responsible for proper quality system establishment, in accordance with FDA, cGMP, and ICH Q7A guidance.
MQI provides third-party input, acting in a consulting capacity on these product innovation and approval processes. Our aforementioned experience and track record in overcoming regulatory hurdles, is an invaluable resource our clients rely on. MQI delivers subject expertise and advice including a comprehensive due diligence and audit to potential partners, licensees, sellers, collaborators and investors. We also provide strategic consultation, planning and execution, including appropriate advice for adjustments, alternatives, expansion, and rapid development in preparing products for market.